Terms: = Leukemia AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716
364 results:
1. High throughput screening aids clinical decision-making in refractory acute myeloid leukaemia.
Jessop SJ; Fuentos-Bolanos N; Mayoh C; Dolman MEM; Tax G; Wong-Erasmus M; Ajuyah P; Tyrell V; Marshall GM; Ziegler DS; Lau LMS
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2061. PubMed ID: 38662349
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and Safety in Early application of Ruxolinitib for high-risk: Acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation.
Cheng Q; Tang Y; Liu F; Li X; Fang D
Transpl Immunol; 2024 Apr; 83():101978. PubMed ID: 38302005
[TBL] [Abstract] [Full Text] [Related]
3. Regulatory function and mechanism research for m6A modification WTAP via SUCLG2-AS1- miR-17-5p-jak1 axis in AML.
Liu M; Yu B; Tian Y; Li F
BMC Cancer; 2024 Jan; 24(1):98. PubMed ID: 38233760
[TBL] [Abstract] [Full Text] [Related]
4. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease.
Maas-Bauer K; Stell AV; Yan KL; de Vega E; Vinnakota JM; Unger S; Núñez N; Norona J; Talvard-Balland N; Koßmann S; Schwan C; Miething C; Martens US; Shoumariyeh K; Nestor RP; Duquesne S; Hanke K; Rackiewicz M; Hu Z; El Khawanky N; Taromi S; Andrlova H; Faraidun H; Walter S; Pfeifer D; Follo M; Waldschmidt J; Melchinger W; Rassner M; Wehr C; Schmitt-Graeff A; Halbach S; Liao J; Häcker G; Brummer T; Dengjel J; Andrieux G; Grosse R; Tugues S; Blazar BR; Becher B; Boerries M; Zeiser R
Nat Commun; 2024 Jan; 15(1):446. PubMed ID: 38199985
[TBL] [Abstract] [Full Text] [Related]
5. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.
Chiba M; Shimono J; Suto K; Ishio T; Endo T; Goto H; Hasegawa H; Maeda M; Teshima T; Yang Y; Nakagawa M
Blood; 2024 Apr; 143(14):1379-1390. PubMed ID: 38142436
[TBL] [Abstract] [Full Text] [Related]
6. Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
Hasselbalch HC; Skov V; Kjaer L; Larsen MK
Br J Haematol; 2024 Jan; 204(1):16-18. PubMed ID: 37957927
[TBL] [Abstract] [Full Text] [Related]
7. CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/jak1 pathway.
Tang S; Li S; Shi X; Sheng L; Mu Q; Wang Y; Zhu H; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Anticancer Drugs; 2024 Feb; 35(2):163-176. PubMed ID: 37948318
[TBL] [Abstract] [Full Text] [Related]
8. The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer.
Di Giorgio C; Bellini R; Lupia A; Massa C; Urbani G; Bordoni M; Marchianò S; Rosselli R; De Gregorio R; Rapacciuolo P; Sepe V; Morretta E; Monti MC; Moraca F; Cari L; Ullah KRS; Natalizi N; Graziosi L; Distrutti E; Biagioli M; Catalanotti B; Donini A; Zampella A; Fiorucci S
Cell Oncol (Dordr); 2024 Apr; 47(2):695-710. PubMed ID: 37945798
[TBL] [Abstract] [Full Text] [Related]
9. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
Edahiro Y
Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
[TBL] [Abstract] [Full Text] [Related]
10. XBP1 promotes NRAS
Salimi A; Schemionek-Reinders M; Huber M; Vieri M; Patterson JB; Alten J; Brümmendorf TH; Kharabi Masouleh B; Appelmann I
J Cell Mol Med; 2023 Nov; 27(21):3363-3377. PubMed ID: 37753803
[TBL] [Abstract] [Full Text] [Related]
11. The JAK3
Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
[TBL] [Abstract] [Full Text] [Related]
12. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.
Masarova L; Bose P; Pemmaraju N; Zhou L; Pierce S; Estrov Z; Kantarjian H; Verstovsek S
Acta Haematol; 2023; 146(6):522-529. PubMed ID: 37699357
[TBL] [Abstract] [Full Text] [Related]
13. Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid leukemia Therapy.
Eide CA; Kurtz SE; Kaempf A; Long N; Joshi SK; Nechiporuk T; Huang A; Dibb CA; Taylor A; Bottomly D; McWeeney SK; Minnier J; Lachowiez CA; Saultz JN; Swords RT; Agarwal A; Chang BH; Druker BJ; Tyner JW
Blood Cancer Discov; 2023 Nov; 4(6):452-467. PubMed ID: 37698624
[TBL] [Abstract] [Full Text] [Related]
14. The jak1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.
Hammersen J; Birndt S; Döhner K; Reuken P; Stallmach A; Sauerbrey P; La Rosée F; Pfirrmann M; Fabisch C; Weiss M; Träger K; Bremer H; Russo S; Illerhaus G; Drömann D; Schneider S; La Rosée P; Hochhaus A
Leukemia; 2023 Sep; 37(9):1879-1886. PubMed ID: 37507425
[TBL] [Abstract] [Full Text] [Related]
15. Characteristics of Molecular Genetic Mutations and Their Correlation with Prognosis in Adolescent and Adult Patients with Acute Lymphoblastic leukemia.
Sun X; Liu X; Li Y; Shi X; Li Y; Tan R; Jiang Y; Sui X; Ge X; Xu H; Wang X; Fang X
Oncology; 2024; 102(1):85-98. PubMed ID: 37437551
[TBL] [Abstract] [Full Text] [Related]
16. Palmitoylation-dependent control of jak1 kinase signaling governs responses to neuropoietic cytokines and survival in DRG neurons.
Hernandez LM; Montersino A; Niu J; Guo S; Faezov B; Sanders SS; Dunbrack RL; Thomas GM
J Biol Chem; 2023 Aug; 299(8):104965. PubMed ID: 37356718
[TBL] [Abstract] [Full Text] [Related]
17. Achievements and future outlook for JAK inhibitors in polycythaemia vera.
Cakmak I; Harrison C
Expert Opin Pharmacother; 2023; 24(13):1491-1496. PubMed ID: 37343285
[TBL] [Abstract] [Full Text] [Related]
18. Rare Lymphomas: Getting "a Bit Ahead".
Cancer Discov; 2023 Aug; 13(8):OF4. PubMed ID: 37294133
[TBL] [Abstract] [Full Text] [Related]
19. jak1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.
Grant AH; Rodriguez AC; Rodriguez Moncivais OJ; Sun S; Li L; Mohl JE; Leung MY; Kirken RA; Rodriguez G
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047778
[TBL] [Abstract] [Full Text] [Related]
20. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Verstovsek S; Mesa R; Gupta V; Lavie D; Dubruille V; Cambier N; Platzbecker U; Hus M; Xicoy B; Oh ST; Kiladjian JJ; Vannucchi AM; Gerds A; Egyed M; Mayer J; Sacha T; Kawashima J; Morris M; Huang M; Harrison C
Blood Adv; 2023 Jul; 7(14):3582-3591. PubMed ID: 37042865
[TBL] [Abstract] [Full Text] [Related]
[Next]
